Q-omics provides the consensus-scored CCDC138 profile across patient tissues and cancer cell-line models. CCDC138 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC138 is differentially expressed in 17, with the highest sampling consensus in STAD. Additionally, CCDC138 RNA expression shows 21,050 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, STAD, and LSCC as cancer lineages where CCDC138 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC138 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC138 survival associations across molecular data types. CCDC138 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC138 RNA expression–survival associations across cancer types. High CCDC138 expression shows unfavorable associations in ACC, KIRP, MESO, LGG and LIHC, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC138 RNA expression.
This table summarizes CCDC138 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC138. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC138 shows lower tumor expression in THCA and KICH and higher tumor expression in STAD, BLCA, LIHC and COAD. The STAD box plot shows higher CCDC138 RNA expression in tumor versus normal tissue (log2 FC = +1.099, t-test p < 0.001).
This table shows molecular features associated with CCDC138 in patient tissues and cancer cell lines. In patient samples, CCDC138 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC138 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
